Skip to main content
. 2026 May 27;6(5):1220–1238. doi: 10.1158/2767-9764.CRC-25-0648

Figure 8.

Figure 8.

AOH1996 synergizes with cisplatin in vivo and reduces cisplatin-associated toxicity. A, HeLa xenograft tumor volumes after monotherapy with mock treatment (black), cisplatin (blue), or AOH1996 (red). B, Corresponding mouse body weights. C, Kaplan–Meier survival analysis of mice treated with vehicle control, 8 mg/kg cisplatin (blue), or 100 mg/kg AOH1996 (red). Both AOH1996 and cisplatin significantly reduce tumor growth and extend survival, though cisplatin is more effective. D, Volume analysis of HeLa xenografts treated with varying doses of AOH1996 reveals that doses below 50 mg/kg exhibit limited monotherapy efficacy. E, Determination of subtherapeutic cisplatin dose. HeLa xenograft volumes of mock (black), subtherapeutic 4 mg/kg (beige), and therapeutic 8 mg/kg (gray) are shown. F, HeLa xenograft volume measurements in mice treated with vehicle, therapeutic-dose cisplatin (8 mg/kg), subtherapeutic-dose cisplatin (4 mg/kg), or the combination of 25 mg/kg AOH1996 and 4 mg/kg cisplatin. G, CaSki xenograft volume measurements in mice treated with vehicle, therapeutic-dose cisplatin (8 mg/kg), subtherapeutic-dose cisplatin (4 mg/kg), or the combination of 25 mg/kg AOH1996 and 4 mg/kg cisplatin. H, Survival analysis of HeLa xenograft–bearing mice. Cutoff set at 290 mm3. I, Survival analysis of CaSki xenograft–bearing mice. J, Final tumor weights at necropsy from HeLa xenografts. K, Final tumor weights at necrophsy from CaSki xenografts. L, Relative body weights of HeLa xenograft–bearing mice throughout treatment. M, Relative body weights of CaSki xenograft–bearing mice throughout treatment. N, Urinary NGAL, a marker of kidney injury, levels in mice treated as indicated. O, Uric acid levels in mice treated as shown. P, Kidney weight at necrophsy in mice treated as indicated. Data represent the mean ± SEM from at least eight mice per group. Statistical comparisons were made using two-way ANOVA for tumor volumes and NGAL levels and log-rank (Mantel–Cox) tests for survival. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.